Thursday, September 18, 2014
Inquirer Daily News

POSTED: Monday, September 23, 2013, 7:08 AM
GlaxoSmithKline's Duncan Learmouth

The United Nations General Assembly gets underway in earnest this week in New York and the Millennium Development Goals for 2015 will get special attention on Wednesday.

The goals were:

1. Eradicate extreme poverty and hunger

POSTED: Thursday, September 19, 2013, 9:29 AM

Google has joined the search for the fountain of youth and ways to alleviate the problems of aging.

The Internet giant, which has changed the world in other ways, announced Wednesday that it was starting a biotech research company called Calico that, "will focus on health and well-being, in particular the challenge of aging and associated diseases," according to the company statement. A link is here.

Calico, which is short for California Life Company, according to Arthur D. Levinson, who will be the chief executive officer and founding investor.

POSTED: Tuesday, September 17, 2013, 9:04 AM
CDC researcher Kitty Anderson examines samples of bacteria. (Photo courtesy of CDC)

Just wipe your nose and stop whining.

Don't run to the doctor and demand that she or he give you a prescription for antibiotics just because you have the sniffles. Drink more water and get a good night's sleep.

If you keep using the antibiotics for middling, run-of-the-mill problems like a runny nose, they might not work when you develop a really nasty infection after landing in the emergency room with some horrible injury and a surgeon has to put your organs and limbs back in their proper places.


POSTED: Monday, September 16, 2013, 9:04 AM

The U.S. Food and Drug Administration put an import alert on medicine produced at the Mohali factory belonging to India-base drugmaker Ranbaxy, which is based in Mumbai and has its U.S. headquarters in Princeton.

The notice is dated Sept. 13 and is posted on the FDA website, with a link here.

The notice means the products can be seized by U.S. authorities without examination. The alert was posted because of concerns about manufacturing problems at the facility.

POSTED: Friday, September 13, 2013, 9:12 AM
Lovaza

Teva Pharmaceuticals USA and Par Pharmaceutical Co., won a federal appeals court patent infringement decision posted Thursday, which - pending FDA approval - will allow the generic drug companies to make cheaper versions of the omega-3 fish oil drug Lovaza, which is sold in the United States by GlaxoSmithKline.

Lovaza is meant to treat high levels of triglycerides, which can be factor in heart disease.

Teva is based in Israel but has its Americas headquarters in North Wales, Montgomery County. GSK is based in London, but has operations in Philadelphia and the surrounding region.

POSTED: Thursday, September 12, 2013, 9:40 AM

Johnson & Johnson's Janssen Pharmaceutical subsidiary said Wednesday that it was recalling one lot of the antipsychotic drug Risperdal Consta.

A link to the recall notice in PDF format is here and gets a brief link on the product web site, which is deep within the Janssen web site.

Janssen's statement says the recall was issued "because the product did not meet our standards."

POSTED: Wednesday, September 11, 2013, 9:19 AM
Pfizer CEO Ian Read

NEW YORK - Pharmaceutical companies have an image problem. They now say they care more about it.

Pfizer collects more money from prescription drugs than any other company on the planet, with 2012 total revenue of $59 billion and net income of $14.6 billion. Finances are part of the dilemma the drugmaker tried to address Tuesday when it invited reporters to its headquarters here to listen to company leaders discuss improvements to research and development of vaccines. Such vaccines can save lives and prevent horrible diseases that can cripple children and ravage societies.

"Frankly, what we do, we believe, is important to society," Pfizer Chief Executive Officer Ian Read said in his opening remarks.

POSTED: Tuesday, September 10, 2013, 9:44 AM
Dawn Pride, of West Philadelphia, holds up her Advair inhaler that help her with chronic asthma. (David M Warren / Staff Photographer)

GlaxoSmithKline's top-selling drug by far is the asthma medication Advair, which accounts for about 20 percent of company revenue. Generic competition got a bit closer to reality on Monday.

Advair is delivered to patients through an inhaler. Besides any existing patents, brand-name drug companies like GSK have hoped that the combination of drug and device would delay U.S. Food and Drug Administration issuance of guidelines for generic manufacturers who hope to make equivalent products.

The FDA issued such guidance on Monday, though the guidance is not final. A link to the technical document is here.

About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
Stay Connected